leukotriene-e4 and Hypertension--Pulmonary

To assess the hemodynamic, oxygen-dynamic and ventilative effects of Zafirlukast in chronic obstructive pulmonary disease (COPD) induced chronic cor pulmonale at acute exacerbation stage and the mechanisms of Zafirlukast efficacy.. Eleven cases of chronic cor pulmonale at acute exacerbation were examined using Swan-Ganz catheter and peripheral intra-artery catheter. The hemodynamic, oxygen-dynamic parameters and respiratory rate, plasma endothelium-1 (ET-1) level, and urea leukotriene E(4) (LTE(4)) level were measured before and at the 1st, 3rd, 5th, 7th, 9th, 12th hour after taking 40 mg Zafirlukast orally. Arterial and mixed venous blood gas analyses were done correspondingly.. The average pulmonary arterial pressure (mPAP) and pulmonary vascular resistance index (PVRI) were lowered at the 3rd hour after taking Zafirlukast by 23% and 36.5%, respectively. They returned to the baseline around 12th hour. Respiratory rate decreased significantly within the 3rd-7th hour after taking Zafirlukast. LTE(4) and ET-1 levels lowered at the 3rd hour and showed a positive correlation with change of mPAP.. Zafirlukast can reduce mPAP, pulmonary vascular resistance (PVR) and does not affect the ambulatory blood pressure monitoring (ABPM) and oxygenation in cases of chronic cor pulmonale at acute exacerbation stage. Zafirlukast may play a role as an alternative to decrease PAP in COPD patients.

Topics: Aged; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Indoles; Leukotriene Antagonists; Leukotriene E4; Male; Oxygen; Phenylcarbamates; Pulmonary Disease, Chronic Obstructive; Respiration; Sulfonamides; Tosyl Compounds

Topics: Adult; Blood Pressure; Case-Control Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Infant; Leukotriene E4; Pulmonary Artery; Tetralogy of Fallot

Leukotrienes have potent biologic actions in various biologic systems. Leukotriene (LT) B4 has inflammatory properties and has been detected in exudates from human inflammatory disease including psoriasis. LTC4, LTD4, and LTE4 have potent bronchoconstrictor actions in vitro and in normal human subjects. LTE4 causes very long-lasting bronchoconstriction. LTC4 and LTD4 are potent vasoconstrictors in coronary and other vascular beds of anesthetized animals. Sulfidopeptide LTs may therefore have a role in asthma and vasospastic disease.

Topics: Animals; Arachidonate Lipoxygenases; Arachidonic Acid; Arachidonic Acids; Asthma; Epoprostenol; Humans; Hypertension, Pulmonary; Indomethacin; Leukotriene B4; Leukotriene E4; Lipoxygenase; Lung; Muscle, Smooth; Research; SRS-A; Vasoconstriction